Last reviewed · How we verify
Sucralfate Suspension
Sucralfate Suspension, developed by LanZhou University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which provides a barrier to generic competition until 2028. The primary risk is the potential increase in competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Sucralfate Suspension |
|---|---|
| Sponsor | LanZhou University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation (PHASE2)
- Endoscopically-delivered Purastat to Treat Bleeding Caused by Radiation Proctopathy (NA)
- MCE Direct Visualization of Drug Behavior in Upper-gastrointestinal Tract
- A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment (PHASE4)
- Pilot Trial on Efficacy of Single Dose Perioperative Intravenous Dexamethasone for Pain Relief After Endoscopic Submucosal Dissection (NA)
- Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sucralfate Suspension CI brief — competitive landscape report
- Sucralfate Suspension updates RSS · CI watch RSS
- LanZhou University portfolio CI